ES2229340T3 - Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa. - Google Patents

Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.

Info

Publication number
ES2229340T3
ES2229340T3 ES97910710T ES97910710T ES2229340T3 ES 2229340 T3 ES2229340 T3 ES 2229340T3 ES 97910710 T ES97910710 T ES 97910710T ES 97910710 T ES97910710 T ES 97910710T ES 2229340 T3 ES2229340 T3 ES 2229340T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
formula
mmol
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97910710T
Other languages
English (en)
Spanish (es)
Inventor
F. George Njoroge
Ronald J. Doll
Stacy W. Remiszewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2229340T3 publication Critical patent/ES2229340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES97910710T 1996-09-13 1997-09-11 Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa. Expired - Lifetime ES2229340T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71298996A 1996-09-13 1996-09-13
US712989 1996-09-13
US87740097A 1997-06-17 1997-06-17
US877400 1997-06-17

Publications (1)

Publication Number Publication Date
ES2229340T3 true ES2229340T3 (es) 2005-04-16

Family

ID=27108923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97910710T Expired - Lifetime ES2229340T3 (es) 1996-09-13 1997-09-11 Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.

Country Status (12)

Country Link
EP (1) EP0929544B1 (enExample)
JP (1) JP2001521489A (enExample)
KR (1) KR20000036111A (enExample)
CN (1) CN1238770A (enExample)
AT (1) ATE282036T1 (enExample)
AU (1) AU4801197A (enExample)
CA (1) CA2266015C (enExample)
DE (1) DE69731544T2 (enExample)
ES (1) ES2229340T3 (enExample)
HU (1) HUP0001109A2 (enExample)
IL (1) IL128931A0 (enExample)
WO (1) WO1998011092A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501617A (en) * 1997-06-17 2001-09-28 Schering Corp 4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine derivatives useful for inhibition of farnesyl protein transferase
ATE276250T1 (de) * 1997-06-17 2004-10-15 Schering Corp Benzo(5,6)cyclohepta(1,2-b)pyridin derivate anwendbar als farnesyl protein tranferase inhibitoren
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CN1289336A (zh) 1998-01-21 2001-03-28 千禧药品公司 趋化因子受体拮抗剂和其使用方法
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1047675A1 (en) 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU4387699A (en) * 1998-07-24 2000-02-14 Russinsky Limited A process for preparing benzocycloheptapyridin-11-ones
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
EP1296949A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ATE365157T1 (de) * 2002-10-03 2007-07-15 Schering Corp Enantioselective alkylierung von trizyklischen verbindungen
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
DE60332862D1 (de) * 2002-11-18 2010-07-15 Schering Corp 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP4769082B2 (ja) * 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
CN113549072B (zh) * 2020-04-23 2024-12-06 鲁南制药集团股份有限公司 一种托法替布杂质ⅰ的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
ATE210652T1 (de) * 1993-10-15 2001-12-15 Schering Corp Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP1380581A1 (en) * 1995-12-22 2004-01-14 Schering Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
JP2001521489A (ja) 2001-11-06
HK1018446A1 (en) 1999-12-24
KR20000036111A (ko) 2000-06-26
CA2266015A1 (en) 1998-03-19
IL128931A0 (en) 2000-02-17
WO1998011092A1 (en) 1998-03-19
DE69731544D1 (de) 2004-12-16
AU4801197A (en) 1998-04-02
HUP0001109A2 (hu) 2001-04-28
CA2266015C (en) 2003-12-30
EP0929544A1 (en) 1999-07-21
EP0929544B1 (en) 2004-11-10
ATE282036T1 (de) 2004-11-15
CN1238770A (zh) 1999-12-15
DE69731544T2 (de) 2005-10-27

Similar Documents

Publication Publication Date Title
ES2229340T3 (es) Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.
US6277854B1 (en) Tricyclic antitumor farnesyl protein transferase inhibitors
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
JP6916795B2 (ja) Ｌｓｄ１阻害剤
ES2238689T3 (es) Compuestos de amida triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
JP6033319B2 (ja) 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
ES2240270T3 (es) Compuestos triciclicos de amida y urea utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
JP2875392B2 (ja) Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式スルホンアミド化合物
CN103201267B (zh) Ampk-激活性杂环化合物以及其使用方法
ES2235252T3 (es) Inhibidores triciclicos de la farnesil proteina transferasa.
ES2248826T3 (es) Amidas triciclicas utiles para la inhibicion de la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
JP2875393B2 (ja) Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式カルバメート化合物
CN112552295A (zh) Kras突变蛋白抑制剂
CA3095912A1 (en) Cereblon ligands and bifunctional compounds comprising the same
ES2849951T3 (es) Derivados de piperidina 4-bencil y 4-benzoil sustituidos
JPH03503650A (ja) Ｃｃｋアンタゴニストとしてのトリプトファン誘導体
KR20240062147A (ko) P53의 돌연변이체를 표적으로 하는 화합물
JP7162591B2 (ja) スピロピペリジン誘導体
KR102834472B1 (ko) 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
WO2023109909A1 (zh) 一种芳杂环类化合物及其制备方法和用途
KR102600391B1 (ko) 삼중고리형 화합물
HU218274B (en) N,n'-bis hydroxyalkyl and alkoxyalkyl-pyridine-2,4-dicarboxylic acid diamide derivatives and pharmaceutical compositions comprising such compounds and process for producing them
CA3225596A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
HK1018446B (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
ES2232888T3 (es) Compuestos utiles para inhibir la farnesil protein transferasa.